Regeneron (REGN): Ready To Go On Approval Of Dupilumab BLA - RBC

October 3, 2016 9:30 AM EDT
Get Alerts REGN Hot Sheet
Price: $362.95 -0.08%

Rating Summary:
    21 Buy, 17 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade REGN Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

RBC Capital analyst, Adnan Butt, reiterated his Outperform rating on shares of Regeneron Pharma (NASDAQ: REGN) with the PDUFA expected March 29th. The analyst believes that REGN/SNY will trade up upon approval. The analyst believes expectations are for a strong launch given a compelling case for unmet need where patients have a quality of life worse than in psoriasis (constant itching, disturbed sleep, depression/ suicidal ideation) and no competitor options near-term.

SOLO 1 and 2 showed clinically and statistically significant improvements in patients with severe atopic dermatitis with placebo adjusted improvements of 27-28% in IGA 0 or 1 and 32-38% in EASI-75 (75% reduction in eczema and severity). Placebo corrected change from baseline in pruritus was 23-33% and EASI 34-38%. Quality of life measures such as DLQI, POEM, and HADS-A and D also showed absolute improvements over placebo ranging from 28-46%, 36-47%, 24-29%, and 33-35%.

No change to the price target of $648.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $402.02 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

RBC Capital, PDUFA

Add Your Comment